Ivermectin 6 mg tablets are a human prescription-drug strength with a specific U.S. regulatory history. The FDA approved a generic 6 mg oral tablet under abbreviated new drug application (ANDA) 215922 on January 22, 2025, alongside a 3 mg version in the same application. This is a product-approval fact, not a dosing recommendation or evidence that the medicine is in stock at a particular pharmacy. A listing for “ivermectin 6 mg” should be checked against the actual prescription product, label and dispensing information before it is treated as an offer for a human medicine.
The 6 mg strength also appears in historical Stromectol records. FDA identified the original Stromectol 6 mg reference-listed drug as no longer marketed in the United States and placed it in the discontinued section of the Orange Book. That status is distinct from the approval of a generic 6 mg tablet: the original brand is not an actively marketed U.S. 6 mg option merely because it remains a reference in an FDA record. FDA also determined that the discontinued 6 mg branded product was not withdrawn for reasons of safety or effectiveness.
For an overview of all human oral formulations, visit oral ivermectin tablets; for a cross-strength discussion of companies and approved generic versions, use generic ivermectin products. This page concentrates on the 6 mg strength itself: what the FDA approved, how an actual U.S. label identifies the tablets, why regulatory status does not equal pharmacy availability and which product details to confirm with a licensed pharmacist. The strength printed on a carton does not tell a person how much ivermectin to take.
The number 6 mg expresses the amount of ivermectin contained in one tablet. It does not specify the total amount prescribed, the number of tablets in a course, the interval between administrations or whether that strength is suitable for any particular patient. A prescription may name a strength and quantity, and the pharmacist checks the specific order against the product being dispensed. The strength is a characteristic of the manufactured item, not a stand-alone treatment plan.
A legitimate U.S. product description should distinguish a human-use oral tablet from products intended for the skin or from veterinary formulations. The dosage form, route, strength and prescription status must all agree. An internet result that says only “ivermectin 6 mg” leaves out key identifying information; the product may be described incompletely, quoted from a historical record or confused with an entirely different dosage form.
The 6 mg strength deserves its own page because an FDA-approved generic and a discontinued branded reference have different regulatory and shopping implications. Readers comparing strengths can consult ivermectin 3 mg tablets, while questions about obtaining a legitimate prescription or selecting a dispensing pharmacy belong on the corresponding access pages.
On January 22, 2025, FDA approved ANDA 215922 for Ivermectin Tablets USP in 3 mg and 6 mg strengths. The approval identifies Rubicon Research Private Limited as the applicant, with Advagen Pharma Ltd acting as its U.S. agent. FDA concluded that the approved products met the requirements for an abbreviated new drug application and were bioequivalent and therapeutically equivalent to the named Stromectol reference-listed products. This is a finding about the products covered by the application, not an endorsement of every item advertised online under the ivermectin name.
The 6 mg strength received a Competitive Generic Therapy designation, and the approval letter identifies Rubicon as the first approved applicant for ivermectin 6 mg tablets in that program. Those regulatory details explain why the 2025 approval is notable; they do not establish which wholesalers, pharmacies or geographic markets currently carry the product. Approval is the permission to market a qualifying drug product under the applicable regulatory framework, whereas retail supply is a separate commercial question.
When interpreting an online description, the most useful checks are the precise strength, the approved application, the responsible labeler and the package identifier. An application number alone is not sufficient to confirm a particular retail offer. A dispensing pharmacy can establish which listed product it intends to supply, while online pharmacy verification addresses how to evaluate the seller rather than the product approval itself.
Stromectol is the historical brand name associated with ivermectin oral tablets. FDA used Stromectol Tablets, 3 mg and 6 mg, under NDA 050742 as the reference-listed products in the 2025 generic approval. A reference-listed drug is part of the FDA approval framework; the term does not promise that a corresponding brand package can currently be ordered. FDA expressly noted that Merck’s Stromectol 6 mg tablets were no longer being marketed in the United States and appeared in the Orange Book discontinued section.
The FDA determination that Stromectol 6 mg was not withdrawn for reasons of safety or effectiveness is a regulatory finding about why generics may still be approved. It must not be rewritten as a claim that the branded 6 mg tablet remains on pharmacy shelves or as a blanket statement about an individual patient’s safety. A purported “brand Stromectol 6 mg” offer merits careful identification and review with the pharmacist, rather than reliance on a familiar name in a sales listing.
Generic ivermectin 6 mg tablets approved under ANDA 215922 are a different product record from the discontinued branded reference. To learn more about the broader brand history, see the Stromectol brand guide; to understand how reference and approved generic products are compared, see Stromectol versus generic ivermectin. This strength-specific page stays focused on what that distinction means when reading a 6 mg label.
One documented U.S. human prescription label is issued by Advagen Pharma Ltd for ivermectin tablets under ANDA 215922. The 6 mg product is recorded with product NDC 72888-207; Rubicon Research Private Limited is named as the manufacturer in that label record. The listed 6 mg tablet is round, white to off-white and bears an arrowhead-style symbol and the imprint I5. These identifying characteristics are specific to this label and should never be assumed to apply to every possible generic ivermectin tablet.
The table illustrates package configurations recorded in that label. It is a factual snapshot of documentation, not a directory of items currently supplied by pharmacies. NDCs identify a labeled drug product and package configuration; the existence of an NDC or marketing entry does not demonstrate that a store has stock, that a wholesaler will fill an order or that a product listing has been independently verified.
Package details may be updated over time, and different approved products can use different labelers, appearances or package codes. Check the exact package presented by the dispensing pharmacy against the patient prescription and its authoritative label information, particularly if an image, imprint or carton description differs from what was expected.
| Documented Advagen 6 mg entry | Identifier | What the label records | What it does not establish |
|---|---|---|---|
| 6 mg oral tablet product | Product NDC 72888-207 | Human prescription tablet; ANDA 215922; labeler Advagen Pharma Ltd | Not an inventory or vendor-authorization statement |
| Bottle presentation | NDC 72888-207-30 | 30 tablets per labeled bottle | Not proof a pharmacy can obtain that package |
| Carton presentation | NDC 72888-207-09 | 100 tablets (10 blisters of 10 tablets each) | Not a guarantee of retail availability |
| Smaller carton presentation | NDC 72888-207-66 | 20 tablets (2 blisters of 10 tablets each) | Not a recommendation for prescribed quantity |
Check the pharmacy-supplied product information in a consistent order: the patient’s name and medication, human oral tablet dosage form, 6 mg strength, dispensing directions as written on the actual prescription, labeler or manufacturer, package description and the pharmacy’s identity. The physical tablet may also have an imprint and characteristic shape. Those visual characteristics should be compared with the exact product the pharmacist dispensed rather than with generic search-result images.
For the documented Advagen 6 mg label, the I5 imprint and arrowhead-style logo are a useful example of product-specific identifiers; a different-looking tablet is not automatically counterfeit because approved generic products may use different physical presentations. Conversely, appearance alone does not prove that an item is authentic. A recognized imprint, an NDC and a legitimate prescription label should be interpreted together with the pharmacy’s dispensing record.
The documented 6 mg Advagen tablet is scored in its labeling, but a score mark should not be interpreted as permission to split, alter or substitute tablets on personal initiative. If the ordered strength, quantity, instructions or appearance does not match what was expected, ask the dispensing pharmacist to resolve the discrepancy before use. The broader process of obtaining a valid prescription is covered under ivermectin prescription requirements.
U.S. labeling for human oral ivermectin tablets includes intestinal strongyloidiasis and onchocerciasis, both caused by certain parasitic worms. The product label identifies approved uses of the medicine; it does not mean that either tablet strength is the right choice for everyone with a suspected infection. The diagnosis, clinical history and prescribing decision are separate from whether a 6 mg tablet exists as an approved item.
In some U.S. clinical settings, a clinician may prescribe oral ivermectin for scabies outside its FDA-approved indications. This is called off-label prescribing and does not convert scabies into an approved indication on the tablet label. A clinician must decide whether such use is appropriate, taking account of the patient and the relevant clinical recommendations. For condition-specific clinical context, see ivermectin for scabies and ivermectin for strongyloidiasis.
A 6 mg tablet contains twice the active ingredient amount of a 3 mg tablet, but that arithmetic does not authorize changing a prescribed strength, combining tablets or replacing one product with another. Nor is oral ivermectin FDA-approved to prevent or treat COVID-19. This page describes a product and its regulatory context; it cannot establish an individual dosage or treatment choice.
Pharmacy catalogs, product databases and search-engine snippets can show a 6 mg tablet because a product is approved or has a recorded package identifier. A listing is not the same as confirmation that the local branch has inventory, can order a particular NDC or can dispense it under a specific prescription. Availability may depend on distributor arrangements, current inventory, pharmacist review, the prescribed item and local dispensing requirements.
Before assuming a listing can be filled, a patient can ask a licensed pharmacy which specific human-use oral tablet it handles, whether the 6 mg strength matches the issued prescription and whether the named generic product is actually available to order or dispense. If a package differs from the prescribed item, the pharmacist can explain whether an authorized substitution or a discussion with the prescriber is needed. Do not assume that a historical Stromectol 6 mg entry represents stock.
For the overall legal acquisition journey, consult buying ivermectin through U.S. pharmacies. Retail pickup and pharmacist discussions are addressed in local ivermectin pharmacy services, while ivermectin delivery covers logistics only after a pharmacy is able to process and dispense a legitimate order.
FDA approval through an ANDA involves meeting applicable standards for a generic drug, including the relevant comparisons with its reference product. The approval of ANDA 215922 specifically recorded bioequivalence and therapeutic equivalence to named Stromectol references. That conclusion should not be expanded to unapproved imported tablets, veterinary products, topical ivermectin or every internet advertisement using the word generic.
Pharmacy substitution is governed by the prescription, applicable state law and the products actually available. An equivalent approved generic may be suitable for dispensing when substitution is permitted, but a pharmacist should not treat a mismatch of strength or dosage form as a routine cosmetic difference. If a prescriber wrote specific instructions, restrictions or a particular formulation, the dispensing pharmacy must take those into account.
A pharmacist can also explain the difference between the company named on a labeling record and the business operating a pharmacy website. An identifiable manufacturer and labeler help establish the drug product’s identity; they do not authenticate the seller. If the pharmacy is an online business, its state authorization, prescription safeguards and pharmacist access must be verified independently of the manufacturer and package information.
Costs for a 6 mg prescription may vary with the particular generic product, tablet quantity, pharmacy, insurance benefits and current purchasing terms. An old cash-price listing, manufacturer reference or NDC record cannot be treated as a reliable quote. A patient can ask the pharmacy for the applicable out-of-pocket amount and whether the product is covered under the plan; broader evergreen pricing factors are discussed in ivermectin pricing and insurance coverage for ivermectin.
The dispensed medicine should have an appropriate pharmacy label, instructions and access to a pharmacist for questions. Patients should review the actual drug information for warnings, possible interactions and relevant clinical precautions, rather than judging safety from tablet strength alone. Ivermectin can cause adverse effects and has important risks in certain circumstances. Pregnancy, other medications and potential coinfections are examples of topics to raise with a qualified clinician; ivermectin safety information provides a broader orientation.
If a prescription bottle, label, strength, imprint or expiration information raises concern, do not try to identify or alter an uncertain medicine solely from online photographs. Keep the original packaging and contact the dispensing pharmacy for a product-specific review before using a tablet in doubt. Approved 6 mg products and the discontinued 6 mg brand are distinct regulatory facts, and neither substitutes for the pharmacist’s verification of the actual dispensed item.
Yes. FDA approved ivermectin 6 mg tablets under ANDA 215922 on January 22, 2025, as part of a generic application that also included 3 mg tablets. That approval does not itself confirm that a particular pharmacy has the 6 mg tablets in stock.
FDA identified Merck’s original Stromectol 6 mg tablets as no longer marketed in the United States and listed them in the Orange Book discontinued section. Their historical role as a reference product does not mean branded 6 mg tablets are currently available for retail purchase.
FDA specifically determined that the branded Stromectol 6 mg product was not withdrawn from sale for reasons of safety or effectiveness. That is a regulatory determination about the product’s withdrawal, not a guarantee that ivermectin is safe or appropriate for every individual.
No. Six milligrams describes the amount of active ingredient in one tablet. It does not determine an individual regimen, total amount, schedule or indication. Those decisions require an authorized prescriber and the instructions on the dispensed prescription.
ANDA 215922 identifies Rubicon Research Private Limited, with Advagen Pharma Ltd as its U.S. agent. A corresponding DailyMed label identifies Advagen as the labeler. This is a documented example; the names alone do not establish current retail supply.
The documented product uses NDC 72888-207, with package-specific extensions such as 72888-207-30 for a labeled 30-tablet bottle. NDCs are identifiers, not proof that a specific package is available or appropriate for a prescription.
That DailyMed label describes a round, white to off-white scored tablet marked with an arrowhead-style symbol and I5. Other approved products may look different, so identification should be confirmed by the dispensing pharmacist using the actual product and label.
Do not change the prescribed strength, quantity or tablet combination on your own. Even when amounts appear arithmetically similar, the prescription directions and dispensing rules matter. Ask the prescriber or pharmacist whether a proposed change is authorized.
No. FDA-approved human oral ivermectin tablets are prescription medicines in the United States. The fact that certain ivermectin topical products have different regulatory status does not make oral tablets over the counter.
No. Approval and current pharmacy inventory are separate matters. Ask a properly licensed pharmacy to verify the prescription, strength, exact product and whether it can actually obtain and dispense that item. Shipping also depends on the pharmacy’s services and applicable jurisdictional requirements.